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Introduction
What is now proved was once only imagin’d.
William Blake, Proverbs of hell (circa 1791)
high-Mobility Group (hMG) are a group of chromosomal 
proteins that assist with transcription, replication, recombination, 
and DnA repair. the hMG proteins are subdivided into three 
superfamilies each containing a characteristic functional domain: 
hMGA – contains an At-hook domain; hMGB – contains 
an hMG-box domain and hMGn – contains a nucleosomal 
binding domain (5, 21, 23, 44).
hMGA (formerly called hMGi/Y/c, now divided into 
hMGA1 and hMGA2) are nonhistone proteins belonging 
to a family of regulatory factors that play a major role in 
maintaining the chromatin architecture and dynamics and 
the regulation of the expression of numerous genes. hMGA1 
and hMGA2 are encoded by two different nuclear genes and 
the hMGA1 transcript produces three different isoforms via 
alternative splicing. hMGA proteins typically contain the 
triple DnA-binding motif (At-hook) that binds to At-rich 
regulatory elements in DnA (34) and an acidic ‘tail’ at the 
carboxy terminus. hMGA are considered master regulators of 
gene expression, though typically not by direct transcriptional 
activation but, rather, by altering DnA conformation so 
as to modulate binding of transcription factors onto the At-
rich promoter/enhancer regions of their target genes; or by 
displacing histone h1, a general transcriptional repressor, from 
transcription initiation sites (11, 36, 43).
hMGA proteins are abundantly and ubiquitously expressed 
in embryonic tissues but hardly detectable in normal adult 
tissues (10, 45). this is only natural as hyperplasticity of 
chromatin, i.e. prodigious availability for various nuclear 
transactions (replication, transcription, repair) is inherent to the 
undifferentiated state of the cell (29). Disturbed regulation – 
usually, up-regulation – of the expression of the hMGA genes 
is a common finding in virtually all human cancers, resulting in 
ectopic expression of proteins characteristic of undifferentiated 
cells (17, 38). in this sense, the hMGA1 gene may be considered 
a classical proto-oncogene. hMGA expression may be up-
regulated by other transcriptional factors as the promoter regions 
of the hMGA1 genes in mammals contain conserved binding 
sites for MYc, AP1 (JUn) and other transcription factors; or 
it may happen via chromosomal rearrangements in the hMGA 
genes which render the mRnA non-repressible by tumour 
suppressor miRnAs such as let-7 (3, 24, 31, 32, 41).
it has been shown that overexpression of hMGA may 
directly inhibit DnA excision repair of any type, nucleotide 
excision (neR) or base excision (BeR), in the nucleus as 
well as in mitochondria (1, 2, 15). What is more, the level of 
expression of hMGA proteins may correlate with the tumour 
stage and propensity for metastasizing in some types of 
NOTHING IN EXCESS – LESSONS LEARNED FROM THE EXPRESSION 
OF HIGH-MOBILITY GROUP PROTEINS TYPE A IN NON-CANCER AND 
CANCER CELLS
Rumena Petkova1, hemanth tummala2, nikolai Zhelev 2
1Scientific Technological Service (STS), Ltd., Sofia, Bulgaria
2University of Abertay Dundee, School of contemporary Sciences, cancer Systems Biology, Dundee, Scotland, UK
correspondence to: nikolai Zhelev
e-mail: n.zhelev@abertay.ac.uk
ABSTRACT
High-mobility group A (HMGA) proteins are major transcription regulators which are abundantly and ubiquitously expressed 
in undifferentiated cells but present at a low level in somatic cells of adult organisms. Up-regulation of HMGA expression is a 
frequent finding in cancer, either via direct stimulation of expression by constitutively expressed proto-oncogenic factors such as 
MYC and JUN or by rearrangements rendering the expression of the HMGA proteins not suppressible by inhibitory factors such 
as miRNAs. Rearrangements of the HMGA genomic loci resulting in disabling of the control mechanisms of their expression are 
often seen in tumours of various origin.
A direct relationship between the level of expression of HMGA in mitochondria and the level of accumulation of oxidative 
damage in cancer cells has been recently noted. On the other hand, mammalian cells deficient in HMGA1 expression are also 
deficient in utilization of glucose and show the impairment in expression of the insulin receptor and the high levels of oxidative 
damage of DNA characteristic of diabetes type 2 and the related condition metabolic syndrome. Insulin resistance and metabolic 
syndrome could be viewed as a premalignant state in which DNA damage is slowly accumulating until the repair machinery of 
the cell cannot withstand the constant oxidative barrage and surrenders to neoplastic transformation.
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tumours, constituting a novel prognostic marker for grade of 
malignancy (20, 22). Overexpression of wild-type or modified, 
cancer-specific HMGA proteins in cancer, however, seems to 
be cell type specific (12, 13).
Specificities in the expression of HMGA in 
normal and cancer cells
in normal cells, hMGA proteins are usually resident to the 
nucleus up to the S/G2 phase of the cell cycle when a fraction of 
hMGA1 migrates to the mitochondria and binds to the control 
element of the mitochondrial DnA known as D-loop (14, 15). 
this is temporary and in non-cancerous cells the migratory 
hMGA1 is usually shuttled back to the nucleus by the 
beginning of M phase. At the time of the relocation of hMGA1 
from the nucleus to the cytoplasm, occurs a post-translational 
phosphorylation of the hMGA1 proteins by cDc2 kinase 
(35), reducing the capacity of the hMGA1 to bind to DnA by 
over an order of magnitude, and thus probably facilitating the 
mobilization of the protein and its shuttling to the cytoplasm in 
the non-cancerous cell. Also, in nontransformed cells hMGA1 
is phosphorylated (i.e. its DnA-binding capacity disabled) 
upon DnA damage and hyperphosphorylated and subsequently 
methylated at the early stages of programmed cell death (38), 
which coincides with the apoptotic condensation of chromatin. 
in many types of tumour cells, however, hMGA1 is readily 
identifiable in mitochondria throughout the cell cycle.
considering the ability of hMGA to suppress DnA 
repair, this may be a pro-carcinogenic mechanism promoting 
genetic instability in the transformed cells. cancer cells are 
prone to DnA damage for yet another reason, namely, the 
higher dose of oxidative damage they receive because of their 
altered metabolism. it has been shown that proper oxidative 
mitochondrial function is essential for proliferation as well 
as for differentiation of undifferentiated cells (embryonic 
stem cells as well as cancer cells), and if it is attenuated for 
some reason, it interferes with the process of differentiation 
(26). Undifferentiated cells show a number of traits which 
distinguish them from differentiated cells in regard to 
metabolism and general biology. Among these are the high-flux 
backbone metabolic state, resembling prokaryotic cells in log 
phase; the low nucleus/cytoplasm ratio; and the lower number 
of mitochondria per cell. therefore, undifferentiated cells are 
typically dependent on anaerobic rather than aerobic means to 
produce energy. cancer cells make no exception as they are 
notoriously ineffective in their utilization of energy sources. 
they rely mainly on glycolysis as a source of chemical energy, 
which results in generation of smaller amounts of AtP and 
higher levels of reactive oxygen species (RoS) than in normal 
cells (19, 30). the latter is, in turn, probably one of the reasons 
for the higher level of DnA damage observed in mitochondrial 
DnA of cancer cells compared to normal cells (7).
Mitochondrial DnA is believed to be particularly sensitive 
to oxidative agents due to its physical proximity to the site 
where the reactive oxygen species are formed and to the lack of 
protective structuring, namely, the absence of histones. Moreover, 
mitochondria are partially deficient in DNA repair mechanisms, 
that is, they do not seem to employ the mechanism of nucleotide 
excision (neR) for the repair of their DnA (40). this could be 
a matter of evolution-imposed parsimony, as usually the major 
type of DnA damage in mitochondrial DnA is oxidative, caused 
by the constant flow of reactive oxygen species generated by 
oxidative phosphorylation. therefore, mechanisms for repair of 
other types of lesions could be deemed redundant and therefore 
lost in the evolutionary process. it seems that the only exception 
is the special case of mismatch repair, a particular type of neR 
endowed with strand specificity, as the DNA polymerases 
which carry out the final step in any type of DNA repair have an 
inherent error rate and may incorporate mismatched nucleotides, 
which, unrepaired, may cause base substitution during the next 
cycle of replication (39). Recombination is also not an option 
for repair of mitochondrial DnA. none of the proteins involved 
in the repair of the mitochondrial genome is coded by its own 
DnA; rather, the relevant information is transcribed using the 
nuclear genes, translated in the cytoplasm and the complete 
repair proteins are subsequently imported in the mitochondrion 
(8). therefore, it seems like the natural target for oxidative 
damage, mitochondrial DnA, is not adequately equipped 
against oxidative assault. in nontransformed cells, however, 
the existing mechanisms seem to be capable to arrest or delay 
oxidative damage accumulation sufficiently well so as for 
the organism to age at a rate typical for the species. in cancer 
cells, however, the overexpression of a set of proteins capable 
of modifying the chromatin architecture, such as hMGA, is 
likely to result in a further plunge in competence for repair of 
their DnA compared to normal cells. quantitative experiments 
have already demonstrated the relationship between the level of 
inducible expression of hMGA in mitochondria and the level 
of mitochondrial dysfunction expressed as accumulation of 
oxidative damage (27).
The role of oxidative damage in the pathogenesis 
of insulin resistance
Apart from cancer, there are other human diseases and conditions 
which have been recently found – quite unexpectedly – to be 
associated with increased level of oxidative damage of DnA. 
experimental proof has been found so far for the association of 
the risk for development of metabolic syndrome (also known 
as X-syndrome, a very common and potentially dangerous 
condition) with certain deficiencies of the mechanism for repair 
of oxidised bases. Metabolic syndrome, as defined by the set of 
criteria of the international Diabetes Federation (2006), includes 
abdominal obesity, high triglyceride level, low levels of high 
density lipoprotein cholesterol, arterial blood pressure above 
140/90 and hyperglycemia and/or insulin resistance, the latter 
being a unifying criterion for all current definitions of metabolic 
syndrome. the prevalence of the condition varies between 
ethnic groups but is estimated to have an average prevalence 
of 20-25% in the developed countries, rising to the striking 
40% after the age of 50 (33). Presence of metabolic syndrome 
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constitutes a major risk factor for diabetes mellitus type 2 as well 
as for cardiovascular and cerebrovascular disease.
A linkage has been recently found between the risk for 
developing metabolic syndrome and the Fpg/nei family of DnA 
glycosylases. the latter are bifunctional glycosylase/lyases 
which excise oxidised purines from DnA as well as thymine 
glycol (an exemplary product of oxidation caused by reactive 
oxygen species) and create a single-strand break at the resulting 
abasic site (4). it has already been demonstrated in mouse 
models that the deficiency of one of the mammalian homologues 
of Fpg/nei – neil1, results in hyperglycemia/obesity/kidney 
damage phenotype resembling closely the phenotype of human 
metabolic syndrome (42). Reportedly, mitochondrial DnA from 
Neil1-deficient mice showed significant levels of DNA damage 
compared to mitochondrial DnA of control animals.  earlier, Foti 
et al. (18) described a similar hyperglycemic/obese phenotype 
in mice deficient in the Hmga1 protein and hypothesized that a 
similar mechanism operated for human diabetes type 2. later it 
was demonstrated that human variants of neil1 with decreased 
enzyme activity may, too, result in increased risk for metabolic 
syndrome in man (37). Both findings shared a common feature, 
namely, an unusually high level of oxidative damage found in 
the DnA of the affected cells.
Increased levels of oxidative stress have been identified as 
a hallmark of insulin-resistant diabetes and atherosclerosis for 
decades now (6), but whether it was the DnA damage that induced 
and promoted the pathological process or was it a product of the 
impact of other factors that brought the insulin resistance about 
it was not clear. over 20 variants of the human hMGA1 gene 
have been identified so far, with at least four of them resulting 
in severe insulin resistance and as of now, it seems very likely 
that variants in the hMGA1 gene are directly responsible for 
at least a proportion of the cases of diabetes type 2 (9). these 
diabetes type 2-linked hMGA1 variants affect the coding 
portions of the gene as well as the untranslated region, which 
indicates that the preservation of the wildtype protein sequence 
and the regulation of its expression are equally important. the 
study in question (9) has not identified homozygous carriers 
of the ‘high-risk’ variants, which may mean that carriership of 
two defective copies may dramatically decrease the fitness of 
the carrier individuals, causing them to die prenatally or not live 
long enough to reproduce. Actually, previous observations made 
on mice carrying two copies of a null Hmga allele (18) support 
this notion. taken together with the habitually high level of 
oxidative DnA damage seen in insulin resistant cells, recently, 
a hypothesis has been proposed placing faulty management 
of DnA damage in charge of the etiopathogenesis of insulin 
resistance and atherosclerosis (25, 28) but still answers remain 
elusive as to the exact induction mechanism.
Conclusion – the excess of courtesy is discourtesy, 
or why X-syndrome is not just a fashionable term
hMGA proteins are capable of reorganizing architecture of 
the chromatin, giving access to major regulatory elements and 
recruiting and organizing transcription factors. Unlike most 
DnA-binding proteins, hMGA proteins bind to chromatin 
independently of the underlying DnA sequence, rather, their 
functional specificity depends on interactions with regulatory 
factors and/or on their ability to target particular chromatin 
conformations. this ensures the versatility, and, at the same 
time, the specificity of the interaction between HMGA 
and its target DnA domains. taken together with its direct 
dependence on potent proliferation factors such as MYc and 
JUn and their suppressive activity over DnA repair, hMGA1 
seems to make an exceptionally good up-regulation target in 
carcinogenesis and is indeed overexpressed in the majority of 
cancers. the hMGA proteins are both targets and modulators 
of differentiating agents, such as retinoic acid.  targeted 
disruption of the hMGA-DnA binding has already been 
proposed as an anticancer strategy (16, 24). on the other hand, 
in non-cancerous cells, if the expression level of hMGA1 is 
low, the associated oxidative damage would not only produce 
the metabolic phenotype of impaired glucose tolerance but 
could, in time, result in just enough unrepaired DnA damage 
so as to launch an oncogenic transformation.
All in all, it seems that both too little and too much 
of hMGA do not do any good to a cell, be it a normal or a 
tumour cell, as the level of oxidative damage increases either 
way. it could be hypothesized that inherently low levels of 
hMGA (e.g. resulting from polymorphisms in the respective 
gene/s) may, via different mechanisms, bring about decreased 
efficiency of protection of the DNA of the cell against oxidative 
damage and, respectively, accumulation of potentially 
carcinogenic oxidative lesions. once the cell is transformed, 
it may further deploy the mechanism characteristic of cancer 
cells so as to increase the level of genomic rearrangements, 
resulting in constitutive overexpression of hMGA and 
subsequent unleashing of malignant growth. in this light, 
insulin resistance and metabolic syndrome could be viewed 
as a long-term, low-grade premalignant state in which DnA 
damage is slowly but irrevocably accumulating until the repair 
machinery of the cell cannot withstand the constant oxidative 
barrage and surrenders to neoplastic transformation. certainly, 
the underlying mechanism is not that simple, as living cells 
possess additional intricate machinery keeping the integrity of 
their DNA in check and/or sacrifice irreversibly damaged cells. 
it is likely, however, that hMGA1 is among the most important 
participants in the process of managing the fine balance between 
normal and pathological metabolic state, which becomes even 
finer and more difficult to manage as the organism ages. Since 
the prevalence of both cancer and insulin resistance increase 
with age, it is hard to differentiate the impact of the one or the 
other, but it could reflect a chain of probabilities and events that 
are causally linked but its determining factors are too strictly 
regu lated in the normal cells so that the resulting effects only 
show with advancement of the aging process.
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